Biomarin Pharmaceutical (NASDAQ:BMRN) just reported results for the first quarter of 2024.
- Biomarin Pharmaceutical reported earnings per share of 71 cents. This was above the analyst estimate for EPS of 34 cents.
- The company reported revenue of $648.83 million.
- This was 0.45% worse than the analyst estimate for revenue of $651.79 million.